Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Feature
Nature Biotechnology 25, 1395–1402 (1 December 2007) | doi:10.1038/nbt1207-1395
Antivirals become a broader enterprise
Abstract
Efforts to develop antiviral therapeutics had mostly sputtered before the AIDS epidemic spurred an intensive search for new drugs to counter the human immunodeficiency virus (HIV). Added impetus has been provided by the frustrations and failures encountered during HIV vaccine development (Box 1).
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
